Samyang Biopharm USA, Inc is the new subsidiary of Samyang Biopharmaceuticals Corporation (Korea) and will focus on biologics development in oncology and rare disease. The company will seek late preclinical to Phase 1 antibody, antibody drug conjugate, and recombinant proteins for global in-licensing to develop in the United States.
You may find a link to Samyang Holdings Corporation (Korea) here
In-license preclinical to Phase I biologics (antibodies, antibody drug conjugates, or recombinant proteins) in immuno-oncology or rare/orphan disease for global development with trials initiating in the US.
Become an established, development-stage global Biotech with a pipeline of value-added biologics in oncology and rare disease.
Building a strong team has been a core focus. “We want to remain small in size to ensure we have very little bureaucracy and can maintain nimble, quick decision-making throughout our process.” That requires extreme talent, and that is what we have done. The reputation and experience of our key management is the best in the industry: Helen Lee (Clinical), Barbara Natke (BD) and Sean McKenna (Research).
Located in Cambridge, MA, we placed ourselves right in the middle of the Biotech hub to ensure immediate access to the best innovation. Our leadership team offers a valuable network of connections both locally and on an international level.
With a focus on immuno-oncology and rare diseases, Samyang Biopharm USA seeks partnering opportunities to in-license or co-develop first in class assets for advancement from preclinical study to clinical trial.
